21.32 0.00 (0.00%)
After hours: 4:00PM EDT
|Dr. Stephen J. Farr||Co-Founder, CEO, Pres & Director||867.95k||5.7M||1959|
|Mr. Michael P. Smith||Exec. VP, CFO, Treasurer & Sec.||573.34k||1.7M||1968|
|Dr. Bradley S. Galer||Exec. VP & Chief Medical Officer||582.08k||N/A||1962|
|Dr. Gail M. Farfel||Exec. VP & Chief Devel. Officer||568.5k||N/A||1964|
|Mr. Ashish M. Sagrolikar||Exec. VP & Chief Commercial Officer||541.24k||N/A||1967|
|Mr. Jeff D. Durflinger||VP of Technical Operations & Product Supply||N/A||N/A||1961|
|Ms. Shawnte M. Mitchell||Exec. VP, Gen. Counsel & Sec.||N/A||N/A||1978|
|Melinda Baker||Sr. Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Bret E. Megargel||VP of Corp. Devel.||N/A||N/A||1969|
|Mr. Stephen H. Jenner||VP of Marketing||N/A||N/A||1968|
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Zogenix, Inc.’s ISS governance QualityScore as of 31 October 2019 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 7; Compensation: 7.